All In Biotech

Free tool

FAERS Monitor: Viokace

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 022542 or its brand name (Viokace, Pancrelipase (Amylase, Lipase, Protease)). Reports on generic versions are filed under their own applications.

Reports

2,537

Serious

2,257

89% of reports

Hospitalization

1,448

Death reported

286

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea256
  • nausea158
  • dyspnoea135
  • fatigue133
  • off label use131
  • vomiting126
  • abdominal pain118
  • asthenia118
  • pyrexia115
  • pain108
  • weight decreased107
  • drug ineffective98
  • pneumonia94
  • acute kidney injury88
  • dizziness86

Reports by year received

View as table
YearReports
200422
200516
200610
200713
200812
200921
201045
201149
201253
201366
201456
201593
201698
2017103
2018118
2019141
2020170
2021235
2022271
2023260
2024276
2025269
2026140

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,622 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
acute kidney injurySignal884.83.9260
abdominal painSignal1184.23.5288
diarrhoeaSignal2563.32.9418
weight decreasedSignal1073.22.6160
pyrexiaSignal1152.82.3129
astheniaSignal1182.62.2117
pneumoniaSignal942.42.077
vomitingSignal1262.21.985
dyspnoea1352.01.766
nausea1581.71.442
pain1081.51.216
dizziness861.41.211
fatigue1331.41.216
off label use1311.21.06
drug ineffective980.60.525

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.